0

Close
 
Upcoming Allied Market Research
2023
Antibody Production Market

Antibody Production Market

by Process (Upstream Processing, Downstream Processing, Filtration) and by End User (Pharmaceutical Biotechnology Companies, Diagnostic Laboratories, Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies
Report Code: A03233
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Antibody Production Market

Request Now !

Antibodies, also known as immunoglobulins, are large Y-shaped proteins that are produced by plasma cells, and are used by immune system to neutralize pathogens such as bacteria and viruses. The immune system produces antibodies in response to foreign bodies or antigens entering inside the body. The two major types of antibodies are monoclonal and polyclonal antibodies, which can also be produced by hybridoma- and hybridoma-free techniques.

Increase in adoption of targeted immunotherapy, improved approval rate of therapeutic antibodies by regulatory authorities, and rise in R&D expenditure of pharmaceutical and biotechnology companies drive the growth of the global antibody production market. In addition, increase in incidence of infectious diseases and growth in demand for protein therapeutics fuel the market growth. However, high cost of primary antibodies restrains the market growth. Increase in R&D activities for the development of advanced antibodies and the growth in adoption of targeted immunotherapy are expected to provide opportunities for the market.

The global antibody production market is segmented by process, end user, and region. Based on process, the market is categorized into upstream processing, downstream processing, and filtration. The upstream processing segment is further divided into bioreactors and consumables.

The bioreactors segment is subdivided into large-scale bioreactors and single-use bioreactors, whereas consumables segment is subsegmented into media and buffers & reagents. The market by filtration is classified into filtration systems and filtration consumables & accessories. By end user, the market is classified into pharmaceutical & biotechnology companies, diagnostic laboratories, and research institutes. Geographically, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

The companies profiled in the report are GeneTex, Inc., Thermo Fisher Scientific, Inc., Eli Lilly and Company, Merck KGaA, Pall Corporation, Sigma-Aldrich Corporation, Eppendorf AG, Cellab GmbH, Abcam PLC, and FiberCell Systems Inc.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided, which helps to determine the prevailing opportunities.
  • Key players are profiled and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the global market.
  • Extensive analysis represents the use of antibody in the treatment of infectious diseases such as pneumonia, food poisoning, urethritis, and others.

 Antibody Production Market Report Highlights

Aspects Details
By Process
  • Upstream Processing
    • Bioreactors
      • Large-scale Bioreactors
      • Single-use Bioreactors
    • Consumables
      • Media
      • Buffers & Reagents
  • Downstream Processing
    • Chromatography Systems
    • Chromatography Resins
  • Filtration
    • Filtration Systems
    • Filtration Consumables & Accessories
By End User
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Research Institutes
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Thermo Fisher Scientific, Inc., Cellab GmbH, Eli Lilly and Company, Pall Corporation, Abcam PLC, FiberCell Systems Inc, Merck KGaA, Sigma-Aldrich Corporation, Eppendorf AG, GeneTex, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PROCESS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Process

    • 4.2. Upstream Processing

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Bioreactors

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Large-scale Bioreactors

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Single-use Bioreactors

          • 4.2.4.2.1. Market Size and Forecast

      • 4.2.4. Consumables

        • 4.2.4.1. Market Size and Forecast

        • 4.2.4.2. Media

          • 4.2.4.2.1. Market Size and Forecast

        • 4.2.4.2. Buffers Reagents

          • 4.2.4.2.1. Market Size and Forecast

    • 4.3. Downstream Processing

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Chromatography Systems

        • 4.3.4.1. Market Size and Forecast

      • 4.3.4. Chromatography Resins

        • 4.3.4.1. Market Size and Forecast

    • 4.4. Filtration

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

      • 4.4.4. Filtration Systems

        • 4.4.4.1. Market Size and Forecast

      • 4.4.4. Filtration Consumables Accessories

        • 4.4.4.1. Market Size and Forecast

  • CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Pharmaceutical Biotechnology Companies

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Diagnostic Laboratories

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Research Institutes

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Process

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Antibody Production Market

        • 6.2.5.1. Market Size and Forecast, By Process
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Antibody Production Market

        • 6.2.6.1. Market Size and Forecast, By Process
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Antibody Production Market

        • 6.2.7.1. Market Size and Forecast, By Process
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Process

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Antibody Production Market

        • 6.3.5.1. Market Size and Forecast, By Process
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Antibody Production Market

        • 6.3.6.1. Market Size and Forecast, By Process
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Antibody Production Market

        • 6.3.7.1. Market Size and Forecast, By Process
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Antibody Production Market

        • 6.3.8.1. Market Size and Forecast, By Process
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Antibody Production Market

        • 6.3.9.1. Market Size and Forecast, By Process
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Antibody Production Market

        • 6.3.10.1. Market Size and Forecast, By Process
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Antibody Production Market

        • 6.3.11.1. Market Size and Forecast, By Process
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Process

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Antibody Production Market

        • 6.4.5.1. Market Size and Forecast, By Process
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Antibody Production Market

        • 6.4.6.1. Market Size and Forecast, By Process
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Antibody Production Market

        • 6.4.7.1. Market Size and Forecast, By Process
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Antibody Production Market

        • 6.4.8.1. Market Size and Forecast, By Process
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Antibody Production Market

        • 6.4.9.1. Market Size and Forecast, By Process
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Antibody Production Market

        • 6.4.10.1. Market Size and Forecast, By Process
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Antibody Production Market

        • 6.4.11.1. Market Size and Forecast, By Process
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Antibody Production Market

        • 6.4.12.1. Market Size and Forecast, By Process
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Antibody Production Market

        • 6.4.13.1. Market Size and Forecast, By Process
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Process

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Antibody Production Market

        • 6.5.5.1. Market Size and Forecast, By Process
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Antibody Production Market

        • 6.5.6.1. Market Size and Forecast, By Process
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Antibody Production Market

        • 6.5.7.1. Market Size and Forecast, By Process
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Antibody Production Market

        • 6.5.8.1. Market Size and Forecast, By Process
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Antibody Production Market

        • 6.5.9.1. Market Size and Forecast, By Process
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Antibody Production Market

        • 6.5.10.1. Market Size and Forecast, By Process
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. GeneTex, Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Thermo Fisher Scientific, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Eli Lilly And Company

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Merck KGaA

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Pall Corporation

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Sigma-Aldrich Corporation

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Eppendorf AG

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Cellab GmbH

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Abcam PLC

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. FiberCell Systems Inc

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANTIBODY PRODUCTION MARKET FOR FILTRATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANTIBODY PRODUCTION MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ANTIBODY PRODUCTION MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL ANTIBODY PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA ANTIBODY PRODUCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 12. NORTH AMERICA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 13. U.S. ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 14. U.S. ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. CANADA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 16. CANADA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 18. MEXICO ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE ANTIBODY PRODUCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 21. EUROPE ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 23. FRANCE ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 25. GERMANY ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. ITALY ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 27. ITALY ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 29. SPAIN ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 30. UK ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 31. UK ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 33. RUSSIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 35. REST OF EUROPE ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC ANTIBODY PRODUCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. CHINA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 40. CHINA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 42. JAPAN ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 43. INDIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 44. INDIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 46. SOUTH KOREA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 48. AUSTRALIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 50. THAILAND ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 52. MALAYSIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 54. INDONESIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA ANTIBODY PRODUCTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 59. LAMEA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 61. BRAZIL ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 63. SOUTH AFRICA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 65. SAUDI ARABIA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. UAE ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 67. UAE ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 69. ARGENTINA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA ANTIBODY PRODUCTION, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 71. REST OF LAMEA ANTIBODY PRODUCTION, BY END USER, 2022-2032 ($MILLION)
  • TABLE 72. GENETEX, INC.: KEY EXECUTIVES
  • TABLE 73. GENETEX, INC.: COMPANY SNAPSHOT
  • TABLE 74. GENETEX, INC.: OPERATING SEGMENTS
  • TABLE 75. GENETEX, INC.: PRODUCT PORTFOLIO
  • TABLE 76. GENETEX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 78. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 79. THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 80. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 81. THERMO FISHER SCIENTIFIC, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 83. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 84. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 85. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 86. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. MERCK KGAA: KEY EXECUTIVES
  • TABLE 88. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 89. MERCK KGAA: OPERATING SEGMENTS
  • TABLE 90. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 91. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. PALL CORPORATION: KEY EXECUTIVES
  • TABLE 93. PALL CORPORATION: COMPANY SNAPSHOT
  • TABLE 94. PALL CORPORATION: OPERATING SEGMENTS
  • TABLE 95. PALL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 96. PALL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. SIGMA-ALDRICH CORPORATION: KEY EXECUTIVES
  • TABLE 98. SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
  • TABLE 99. SIGMA-ALDRICH CORPORATION: OPERATING SEGMENTS
  • TABLE 100. SIGMA-ALDRICH CORPORATION: PRODUCT PORTFOLIO
  • TABLE 101. SIGMA-ALDRICH CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. EPPENDORF AG: KEY EXECUTIVES
  • TABLE 103. EPPENDORF AG: COMPANY SNAPSHOT
  • TABLE 104. EPPENDORF AG: OPERATING SEGMENTS
  • TABLE 105. EPPENDORF AG: PRODUCT PORTFOLIO
  • TABLE 106. EPPENDORF AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. CELLAB GMBH: KEY EXECUTIVES
  • TABLE 108. CELLAB GMBH: COMPANY SNAPSHOT
  • TABLE 109. CELLAB GMBH: OPERATING SEGMENTS
  • TABLE 110. CELLAB GMBH: PRODUCT PORTFOLIO
  • TABLE 111. CELLAB GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ABCAM PLC: KEY EXECUTIVES
  • TABLE 113. ABCAM PLC: COMPANY SNAPSHOT
  • TABLE 114. ABCAM PLC: OPERATING SEGMENTS
  • TABLE 115. ABCAM PLC: PRODUCT PORTFOLIO
  • TABLE 116. ABCAM PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. FIBERCELL SYSTEMS INC: KEY EXECUTIVES
  • TABLE 118. FIBERCELL SYSTEMS INC: COMPANY SNAPSHOT
  • TABLE 119. FIBERCELL SYSTEMS INC: OPERATING SEGMENTS
  • TABLE 120. FIBERCELL SYSTEMS INC: PRODUCT PORTFOLIO
  • TABLE 121. FIBERCELL SYSTEMS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODY PRODUCTION MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANTIBODY PRODUCTION MARKET
  • FIGURE 3. SEGMENTATION ANTIBODY PRODUCTION MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANTIBODY PRODUCTION MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANTIBODY PRODUCTION MARKET
  • FIGURE 11. ANTIBODY PRODUCTION MARKET SEGMENTATION, BY BY PROCESS
  • FIGURE 12. ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANTIBODY PRODUCTION MARKET FOR FILTRATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. ANTIBODY PRODUCTION MARKET SEGMENTATION, BY BY END USER
  • FIGURE 16. ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ANTIBODY PRODUCTION MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. ANTIBODY PRODUCTION MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: ANTIBODY PRODUCTION MARKET
  • FIGURE 25. Top player positioning, 2022
  • FIGURE 26. GENETEX, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 27. GENETEX, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 28. GENETEX, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 29. THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 30. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 31. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 32. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 33. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 34. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 35. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. MERCK KGAA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. PALL CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. PALL CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. PALL CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. SIGMA-ALDRICH CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. SIGMA-ALDRICH CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. SIGMA-ALDRICH CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. EPPENDORF AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. EPPENDORF AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. EPPENDORF AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. CELLAB GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. CELLAB GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. CELLAB GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. ABCAM PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ABCAM PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. ABCAM PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. FIBERCELL SYSTEMS INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. FIBERCELL SYSTEMS INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. FIBERCELL SYSTEMS INC: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Antibody Production Market

Start reading.
This Report and over 68,075+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers